Amorphous Efinaconazole Solid Dispersion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amorphous drug forms, such as efinaconazole, exhibit poor stability and thermodynamic instability, leading to short storage periods and difficulty in controlling drug release and blood concentration, which is a challenge in formulations for onychomycosis treatment.
Innovation Solution
A solid dispersion of amorphous efinaconazole is created using stabilization carriers like hydroxypropyl methylcellulose, polyvinylpyrrolidone, and ethyl cellulose, with a weight ratio of 1:0.1 to 1:5, which is prepared by dissolving the components in a solvent and filtering and drying the solution to maintain the amorphous form and enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amorphous form of efinaconazole is used, then bioavailability is improved, but stability deteriorates
Solution Approach 1:
The patent creates a composite solid dispersion system combining amorphous efinaconazole with stabilizing excipients (polymers, sugars, or amino acids) in a specific weight ratio (1:0.1 to 1:5). This composite structure maintains the high bioavailability of the amorphous form while the stabilizing components prevent degradation and improve storage stability.
Solution Approach 2:
The patent changes the physical state parameter of efinaconazole from crystalline to amorphous form, and further optimizes the molecular arrangement parameters by controlling the solid dispersion structure. This parameter change enables improved dissolution and bioavailability while the stabilizing excipients control the thermodynamic instability of the amorphous form.
2Quantity of substance
If amorphous form of efinaconazole is used, then solubility is improved, but storage period deteriorates
Solution Approach 1:
The solid dispersion forms a composite material where amorphous efinaconazole is dispersed in a stabilizing matrix of excipients. This composite structure maintains high solubility characteristics of the amorphous form while the stabilizing matrix extends the storage period by preventing degradation.
Solution Approach 2:
The stabilizing excipients (polymers, sugars, or amino acids) act as intermediary substances that protect the amorphous efinaconazole from environmental factors and degradation, thereby extending storage period while maintaining the solubility advantages of the amorphous form.
3Productivity
If amorphous form of efinaconazole is used, then dissolution rate is improved, but control over release and blood concentration deteriorates
Solution Approach 1:
The patent optimizes parameters including the weight ratio of efinaconazole to stabilizing excipient (1:0.1 to 1:5), the molecular structure of excipients, and processing conditions to achieve controlled release characteristics while maintaining high dissolution rate from the amorphous form.
Solution Approach 2:
The composite solid dispersion structure allows the stabilizing excipients to modulate the release characteristics of efinaconazole, providing control over release rate and blood concentration while maintaining the high dissolution rate advantage of the amorphous form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion achieves improved stability and bioavailability of efinaconazole, minimizing thermodynamic deformation due to ambient temperature and humidity, thus extending the applicability of efinaconazole formulations beyond topical use to oral and transdermal applications.
Implementation Method 1
a solid dispersion including an amorphous form of efinaconazole and at least one stabilization carrier
Implementation Method 2
undergoes minimal thermodynamic deformation when exposed to ambient temperature and humidity, achieving improved stability
Implementation Method 3
dissolving efinaconazole and at least one stabilization carrier selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone (PVP), polyacrylic acid (PAA), saccharin, and malonic acid in a solvent
Implementation Method 4
filtering and drying the solution
Implementation Method 5
filtering and drying the solution
Data Source
AI summary
A solid dispersion of amorphous efinaconazole and a method for preparing the same are proposed. The solid dispersion includes an amorphous form of efinaconazole and at least one stabilization carrier selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone (PVP), polyacrylic acid (PAA), saccharin, and malonic acid. The solid dispersion undergoes minimal thermodynamic deformation when exposed to ambient temperature and humidity, achieving improved stability, while maintaining the inherent improved stability and bioavailability of amorphous efinaconazole.